PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J G Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P Sutter, Thorben W Fründt, Ansgar W Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze
Frontiers in immunology 2024;14():1326078